Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin's disease

An accurate initial staging of patients with Hodgkin's disease (HD) is important for the evaluation of clinical stage and risk factors, which are crucial for the choice of an appropriate treatment. 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) is useful for detecting active tu...

Full description

Saved in:
Bibliographic Details
Published in:Annals of hematology 2002, Vol.81 (1), p.20-25
Main Authors: WEIHRAUCH, M. R, RE, D, WOLF, J, SCHICHA, H, DIEHL, V, TESCH, H, BISCHOFF, S, DIETLEIN, M, SCHEIDHAUER, K, KRUG, B, TEXTORIS, F, ANSEN, S, FRANKLIN, J, BOHLEN, H
Format: Article
Language:English
Subjects:
Adult
Biological and medical sciences
Female
Fluorodeoxyglucose F18
Hematologic and hematopoietic diseases
Hodgkin Disease - diagnostic imaging
Hodgkin Disease - pathology
Humans
Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
Male
Medical sciences
Middle Aged
Neoplasm Staging
Radiopharmaceuticals
Tomography, Emission-Computed
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:An accurate initial staging of patients with Hodgkin's disease (HD) is important for the evaluation of clinical stage and risk factors, which are crucial for the choice of an appropriate treatment. 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) is useful for detecting active tumor tissue in patients with lymphoproliferative diseases and may contribute to conventional staging methods in patients with HD. Twenty-two patients who presented with newly diagnosed HD underwent conventional staging methods including computed tomography (CT) as well as FDG PET. Lesions apparent in FDG PET and CT were correlated to each other. Seventy-seven lesions were observed either in PET or CT or in both. In 48 (62%) lesions PET and CT were both positive. In 20 (26%) sites, PET was positive and CT negative. Of 22 patients (18%) 4 were upstaged due to these positive PET findings, and as a result one patient received a different therapeutic regimen. PET failed to detect nine (12%) CT-positive sites in six patients. Statistically, these data are reflected by a sensitivity for PET and CT of 88% and 74%, respectively. Specificity of both imaging modalities was 100%. PET can contribute valuable information as an additional staging examination and led to an upstaging in some patients with primary HD. However, PET should not be used as the only imaging modality as it failed to detect CT-positive, active tumor regions in some cases.
ISSN:0939-5555
1432-0584
DOI:10.1007/s00277-001-0390-y